From the first study on APOE- and TOMM40-related pharmacogenetics in AD [3], we were able to conclude the following: (i) A multifactorial treatment is useful for patients with dementia in approximately 50% of the cases, stabilizing or improving cognitive deterioration for a transient period of time (<12 months). The gene discussed is APOE; the disease is Alzheimer disease.